Invention Grant
US08722643B2 Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
有权
靶向EN2，PAX2和/或DEFB1用于治疗前列腺疾病
- Patent Title: Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
- Patent Title (中): 靶向EN2，PAX2和/或DEFB1用于治疗前列腺疾病
-
Application No.: US13912841Application Date: 2013-06-07
-
Publication No.: US08722643B2Publication Date: 2014-05-13
- Inventor: Carlton D. Donald
- Applicant: Phigenix, Inc.
- Applicant Address: US GA Atlanta
- Assignee: Phigenix, Inc.
- Current Assignee: Phigenix, Inc.
- Current Assignee Address: US GA Atlanta
- Agency: Andrews Kurth LLP
- Agent Ping Wang
- Main IPC: C12N15/113
- IPC: C12N15/113 ; C07H21/04
Abstract:
The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.
Public/Granted literature
- US20130296403A1 TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS Public/Granted day:2013-11-07
Information query
IPC分类:
